Keyphrases
Kidney Transplant Recipients
100%
Alemtuzumab
100%
Steroid Avoidance
100%
Adjusted Hazard Ratio
66%
Confidence Interval
55%
Antithymocyte Globulin
44%
Acute Rejection
33%
Patient Survival
33%
Adjusted Odds Ratio
33%
Death-censored Graft Survival
33%
Graft Survival
22%
Learning Curve
11%
United States
11%
Tacrolimus
11%
Kidney Transplantation
11%
Maintenance Immunosuppression
11%
Mycophenolate Mofetil
11%
Humanized
11%
New Drugs
11%
Multivariate Analysis
11%
Retrospective Cohort Study
11%
Poor Outcome
11%
Donor-recipient Matching
11%
Multivariate Model
11%
Risk-adjusted
11%
Interaction Terms
11%
Registry Data
11%
Early Withdrawal
11%
Induction Type
11%
Anti-CD52 Monoclonal Antibody
11%
Immunology and Microbiology
Alemtuzumab
100%
Anti-Thymocyte Globulin
40%
Acute Graft Rejection
30%
Immunosuppression
10%
Tacrolimus
10%
Learning Curve
10%
Kidney Transplantation
10%
Mycophenolate Mofetil
10%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
100%
Thymocyte Antibody
40%
Acute Graft Rejection
30%
Cohort Study
10%
Mycophenolate Mofetil
10%
Tacrolimus
10%